Adjuvant interferon alfa treatment for patients with malignant melanoma stimulates transporter proteins associated with antigen processing and proteasome activator 28.
Abuzahra
Faris
F
Department of Dermatology, University Hospital RWTH Aachen, Pauwelsstrasse 30, D-52074 Aachen, Germany.
Heise
Ruth
R
Joussen
Sylvia
S
Dreuw
Alexandra
A
Merk
Hans
H
Zwadlo-Klarwasser
Gabriele
G
Baron
Jens M
JM
D000071181:ATP Binding Cassette Transporter, Subfamily B, Member 2; D000071450:ATP Binding Cassette Transporter, Subfamily B, Member 3; D018528:ATP-Binding Cassette Transporters / Q000096:biosynthesis* / Q000494:pharmacology; D000970:Antineoplastic Agents / Q000494:pharmacology*; D017024:Chemotherapy, Adjuvant; D006801:Humans; D015151:Immunoblotting; D007150:Immunohistochemistry; D016898:Interferon-alpha / Q000494:pharmacology*; D007963:Leukocytes, Mononuclear; D008545:Melanoma / Q000188:drug therapy* / Q000235:genetics*; D009124:Muscle Proteins / Q000494:pharmacology*; D046988:Proteasome Endopeptidase Complex; D011506:Proteins / Q000494:pharmacology*; D012878:Skin Neoplasms / Q000188:drug therapy* / Q000235:genetics*; D015854:Up-Regulation
D000071181:ATP Binding Cassette Transporter, Subfamily B, Member 2; D000071450:ATP Binding Cassette Transporter, Subfamily B, Member 3; D018528:ATP-Binding Cassette Transporters; D000970:Antineoplastic Agents; D016898:Interferon-alpha; D009124:Muscle Proteins; C085047:PSME1 protein, human; D011506:Proteins; C073119:TAP1 protein, human; C071692:TAP2 protein, human; D046988:Proteasome Endopeptidase Complex